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SUMMARY
Epistaxis is one of the most common complaints presenting to emergency departments. The aim of this study is to systematically review and 
critically evaluate the evidence relating to treatment of idiopathic epistaxis for guiding best practice. A comprehensive review of the English 
language literature was performed using PubMed, Embase, Cochrane Library and Central electronic databases. The inclusion criteria were: 
retrospective or prospective or randomised controlled clinical trials which included outcomes in the management of idiopathic epistaxis. Twenty-
three articles met inclusion criteria and were reviewed. Nasal packing still represents the first-line approach to epistaxis, although, at present, it 
appears that there is clear evidence in the literature to suggest that it is less effective and associated with more admissions and longer hospital 
stays than endoscopic electrocoagulation-based management of epistaxis. In conclusion, cauterisation should be the first-line approach for its 
high cost-effectiveness rate and low risk of complications. Further research is urgently needed to assess the efficacy of new biomaterials.
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RIASSUNTO 
L’epistassi è uno dei disturbi più comuni per il quale il paziente si rivolge spesso al pronto soccorso. Questa revisione della letteratura si 
propone di valutare sistematicamente e criticamente gli studi scientifici riguardo il trattamento dell’epistassi idiopatica al fine di ottenere utili 
spunti per la pratica clinica. La ricerca è stata eseguita nei database elettronici: PubMed, Embase, Cochrane e Central. I criteri di inclusione 
sono stati: studi clinici controllati retrospettivi o prospettici o randomizzati o studi su modelli animali che includevano i risultati nella gestione 
dell’epistassi idiopatica. Sono stati individuati 23 articoli che soddisfano i criteri di inclusione. Il tamponamento nasale rappresenta ancora 
l’approccio di prima linea all’epistassi, anche se è evidente dalla letteratura che sia il meno efficace ma il più associato a ricoveri ospedalieri 
di maggior durata rispetto alla chirurgia endoscopica basata sull’elettrocoagulazione. In conclusione appare sempre più evidente che la cau-
terizzazione dovrebbe essere l’approccio di prima linea per l’alto tasso di costo-efficacia e il basso rischio di complicanze. Tuttavia, ulteriori 
ricerche urgenti sono necessarie per validare l’efficacia dei nuovi biomateriali nel trattamento dell’epistassi.
PAROLE CHIAVE: Epistassi • Endoscopia nasale • Cauterizzazione • Arteria sfenopalatina • Embolizzazione
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Introduction
Epistaxis is one of the most common presenting symptom 
to both primary care and accident and emergency depart-
ments. It is thought to affect 10-12% of the population 1, 
and although most cases are self-limiting, some do not re-
solve without intervention. Among these, 80% are from the 
Kiesselbach’s plexus (anterior epistaxis)  2. Interestingly, 
some studies have suggested a positive correlation between 
epistaxis and atmospheric pressure or relative humidity and 
changes in temperature 3 4; others also included allergic rhi-
nitis as one of the main causes of epistaxis 5. Only 6% of 
patients with epistaxis will require medical assistance, and 
cases of severe intractable epistaxis are rare 6. Anterior na-
sal packing, the most common therapy for epistaxis, has 
some limitations including potential for reduced ventilation 
and sleep apnoea, need for analgesics and, in some cases, 
need for prophylactic antibiotics 6. Nasal cautery forms an 
important part of first line management, and is considered 
an important skill for anyone treating epistaxis 7, but is un-
likely to be practiced by non-otolaryngologists. The goal of 
this study was to assess current trends in the management 
of epistaxis in the adult population. 
The aim of this study is to systematically review and criti-
cally evaluate the evidence relating to treatment of idi-
opathic epistaxis in order to guide best practice.
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Search strategy
A comprehensive review of the English language litera-
ture was performed using PubMed, Embase, Cochrane Li-
brary and Central electronic databases using the keyword 
“epistaxis”. The search was executed in March 2016 and 
was limited exclusively to studies published after 2010. It 
yielded a total of 1917 articles. We retrieved the full text of 
any reports potentially meeting inclusion criteria and ex-
amined these independently to determine study eligibility. 
Articles were examined for data resolution with the intent 
to perform a meta-analysis. Different methods of meta-
analyses were considered in reviewing the literature to 
seek results that would provide meaningful analysis with 
the least risk of introducing biases. The inclusion criteria 
were: retrospective or prospective or randomised controlled 
clinical trials which included outcomes in the management 
of idiopathic epistaxis. Exclusion criteria were case reports 
or letters/correspondence to editor; clinical studies includ-
ing the management of epistaxis other than idiopathic or 
mixed cases in which was not possible to extrapolate data 
concerning idiopathic epistaxis; paediatric population or 
animal model; systematic reviews and meta-analyses; non- 
English language manuscripts. To reduce the risk of incom-
plete literature search, a manual search of the references of 
included papers was performed (Fig. 1 for flowchart). Data 
from studies were first extracted and assessed by the prin-
cipal investigator (MG) and thereafter independently by 2 
co-authors (MF and GC) using standardised data forms. 
Quality assessment of studies (QUADAS-2) tool was used 
to evaluate relevant study design characteristics of includ-
ed studies 8. A graphical display of QUADAS-2 results is 
shown in Figure 2.
Results
The search was performed in March 2016 and yielded 
1,917 articles. Moreover, 2 records were added from a 
manual search. Twenty-three articles  9-31 met inclusion 
criteria. An overview of included studies is included in 
Table I.
Nasal packing
The first-line therapy includes anterior-posterior 
synthetic nasal packs and balloons in most stud-
ies 9 10 17 18 20 21 23 26 27 31 32 34 35. More specifically, the effective-
ness of chitosan-based packing was assessed by Kourelis 
and Shikani 24. Chitosan is a natural cationic polysaccha-
ride with well-known powerful haemostatic properties. 
The study group consisted of 35 consecutive patients with 
drug-induced bleeding diathesis. The pack consisted of a 
single sheet of ChitoFlex® (Hemcon, Inc. Portland, OR, 
USA), wrapped around a hydroxylated polyvinylacetal 
sponge (Pope Merocel®, Medtronic, Inc, Minneapolis, 
MN, Usa). The chitosan-based nasal packing achieved 
instant control of bleeding in 32 cases (91%). The mean 
time to bleeding cessation was 3.5 min, ranging from 1 to 
10 min. Moreover, a comparison among different types 
of nasal packings was performed by Dutta et al. 17. Three 
methods were included for the anterior nasal packing, na-
sal packing-merocel (group A), gauze pack lubricated by 
sisomicin ointment (group B) and the same gauze pack 
used with a splint made of a sterilised aluminium foil 
sheet prepared from the cover of the suture materials used 
over the septum (group C), carefully using the paper-cov-
ered surface of the foil to remain in contact with the mu-
cosa to eliminate any systemic absorption of aluminium. 
In 26.7% (n = 64), patients nasal tampon was used (30 for 
epistaxis and 34 for postoperative pack); 39.2% (n = 94) 
of patients were treated with conventional gauze pack with 
sisomycin cream (60 for epistaxis and 34 for post opera-
tive pack). The remaining 34.2% (n = 82) of patients were 
treated with the gauze pack with splint as described ear-
lier (42 for epistaxis and 40 for postoperative pack). The 
“Behavioural Observational Pain Rating Scale” meas-
ured perception of pain during the procedure of packing. 
Fifty-six of 60 patients (93.33%) with gauze packing for 
Fig. 1. Process for sifting search results and selecting studies for inclusion.
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Fig. 2. Proportion of studies with unclear, low and high risk of bias and concerns regarding applicability.


















FloSeal vs nasal packing FloSeal efficacy 75% vs nasal 
packing 85% (NS)
Zou et al. 10 2015 Retrospective 53 Posterior fornix 
of the inferior 
nasal meatus 
Endoscopic bipolar electric 
haemostat vs nasal packing
Lower VAS score, rate of re-
bleeding, and nasal cavity 
adhesion for endoscopic bipolar 
electric haemostat (p < 0.001)
Limura et al. 11 2015 Retrospective 167 Posterior Electrocoagulation vs gauze 
tamponade vs balloon tamponade 
vs follow-up
Recurrent bleeding rates 
based were 8.5% (8/94) for 
electrocoagulation, 41.2% (21/51) 
for gauze tamponade, 50% (1/2) 
for balloon tamponade, and 45% 
(9/20) for follow-up 




4 Anterior Endoscopic electrocautery greater 
palatine artery
No recurrences
Khan et al. 13 2015 Prospective 101 Anterior and 
posterior
FloSeal vs nasal packing Success rate: 14% 
Kilty et al. 21 2014 Prospective 20 Posterior FloSeal Success rate: 80%
Shrestha 14 2014 Retrospective 12 Posterior Endoscopic sphenopalatine ligation Success rate: 100%
Henderson et al. 15 2013 Retrospective 124 Anterior and 
posterior
Electrocautery vs nasal packing The rates of admission and of 
nasal packing reduced with 
the increasing of usage of 
electrocautery (p < 0.001)
Gandomi et al. 16 2013 Retrospective 27 Posterior Endoscopic sphenopalatine artery 
ligation
Success rate 87%
Gottumukkala et a.l 18 2013 Retrospective 84 Posterior Embolisation of one or more external 
carotid artery branches 
Success rate of 89%
Zahed et al. 19 2013 Randomised 
controlled





Anterior Anterior nasal packing vs topical 
tranexamic acid
Recurrence rates: 11% for anterior 
nasal packing, 2.8% for topical 
tranexamic acid (p = 0.018)
Shargorodsky et al 20 2013 Retrospective 147 Anterior and 
posterior
Nasal packing vs silver nitrate vs 
dissolvable packing 
Failure rate 23.8% for silver 
nitrate vs 57.4% for nasal packing 
vs 20% dissolvable packing
continues
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epistaxis experienced severe pain (score 8-10), while 36 
of 42 (85.71%) experienced severe pain when aluminium 
foil splints were used. When nasal tampon was used, only 
4 of 30 patients (13.33%) felt severe pain. This difference 
was statistically significant. Obviously, pain could not be 
recorded if the packing was inserted under general anaes-
thesia during septal surgery. With gauze pack in situ, 22 
of 34 patients (64.70%) experienced moderate pain, in 6 
patients (17.65%) pain was mild and another 6 patients 
felt severe pain. With the addition of septal splint, 10 of 40 
patients (25%) felt mild pain, 28 (70%) had moderate pain 
and 2 patients (5%) experienced severe pain. Nasal tam-
pon packing was almost painless in postoperative group 
as 30 of 34 patients (88.23%) felt only mild pain. The 
episodes of bleeding while packed in situ, within first 48 h 
and forced for repacking, was significantly more preva-
lent among nasal tampon group (group  A) of patients, 
but as such no difference was revealed between groups B 
and C. Regarding experience of bleeding after removal 
of packing, no difference could be observed between 
nasal tampon and gauze packing with or without splint. 
Whereas group  B showed a significantly higher rate of 
bleeding compared to group C. Synaechia formation was 
not lower among group A patients; however, comparison 
with the other two groups showed that the event was more 
common among subjects who belonged to group  B vs 
group C, with a statistically significant difference.
Electrocoagulation
In other studies  9 10 17, the efficacy of nasal packing was 
compared to electrocoagulation. Zou et al.  10 compared 
the outcomes between a group of 15 patients who un-
derwent nasal packing for inferior meatus epistaxis and 
a group of 38 patients who had electrocoagulation using 
bipolar forceps both under general and local anaesthesia. 
The incidence of re-bleeding was significantly lower in 
the electrocoagulation group (0/38) than in the packing 
group (4/15; p = 0.001). Re-bleeding occurred within 48 
and 24 hours after nasal pack removal in three and one 
patient, respectively. All patients with re-bleeding under-
went endoscopic surgery with successful achievement of 
haemostasis. The discomfort visual analogue score (VAS) 
differed significantly between groups, ranging from 1 to 
5 in the surgery group (2.4 ± 1.4) and 6 to 9 in the pack-
ing group (7.6 ± 1.0; p = 0.001). The incidence of nasal 
cavity adhesions was significantly lower in the surgery 
group (2/38) than in the packing group (7/15; p = 0.007). 











Dutta et al. 17 2012 Prospective 132 Anterior Merocel vs gauze with sisomicin 
cream vs gauze with sisomicin 
cream and septal splint
No recurrence rates after removal: 
96.9% for Merocel, 89.4% for 
gauze with sisomicin cream, 
97.6% for gauze with sisomicin 
cream and septal splint (NS)
Mudunuri, Murthy 22 2012 Prospective 42 (conservative 
group)
52 (silver nitrate 
group)
Anterior Silver nitrate vs conservative Failure rate: 26% for silver nitrate, 
30% for conservative
George at al. 23 2012 Retrospective 25 Anterior and 
posterior
Endoscopic sphenopalatine artery 
ligation
Success rate 88%.
Kourelis, Shikani 24 2012 Prospective 35 Anterior Chitosan-based packing Success rate: 91%.
Baloch et al. 25 2012 Retrospective 16 - Angioembolisation Success rate: 87.5% 
Zhang and Qiu 26 2012 Randomised 
controlled
41 (Nd:YAG Laser)
41 (liquid paraffin 
plus antiseptic 
cream)
Anterior Nd:YAG laser vs liquid paraffin plus 
antiseptic cream
Success rate: 85% for Nd:YAG 
laser vs 40% for control group
Strach et al. 29 2011 Retrospective 31 - Endovascular embolisation with 
polyvinyl alcohol particles
Long-term success rate: 93.5%
Eladl et al. 28 2011 Prospective 42 Posterior Endoscopic sphenopalatine artery 
ligation
Success rate: 100%
Lesley et al. 27 2010 Retrospective 20 Posterior Angioembolisation with detachable 
platinum fibered coils
Success rate: 95%
Cotê et al. 30 2010 Prospective 10 Posterior FloSeal Success rate: 80%
Minni et al. 31 2010 Retrospective 48 Anterior and 
posterior
Endoscopic cautery of 
sphenopalatine artery or anterior 
ethmoidal artery
Success rate: 93%
VAS: visual analogue scale; NS: not statistical significant.
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posterior epistaxis. Bleeding sites included the olfac-
tory cleft in 39 of 167 patients (23.4%), middle meatus 
region in 44 patients (26.3%), inferior meatus region in 
36 patients (21.6%), other in 8 patients (4.8%) and un-
known in 40 patients (24.0%). Electrocoagulation was 
performed in 94 patients (56.3%), gauze tamponade in 51 
patients (30.5%), balloon tamponade in 2 patients (1.2%) 
and follow-up in 20 patients (12.0%). Of note, electro-
coagulation was performed using an endoscope in pa-
tients in whom electrocoagulation under direct vision was 
not possible. Monopolar forceps were used on bleeding 
sites where haemostasis using bipolar forceps (straight/
curved) was difficult. Recurrent bleeding occurred in 39 
of 167 patients (23.4%). The bleeding sites at initial ex-
amination in 39 patients with recurrent bleeding were the 
olfactory cleft, middle meatus and inferior meatus, in 6, 
8 and 4 patients, respectively, and was unknown in 21 pa-
tients. The recurrent bleeding rates based on bleeding site 
(patients with recurrent bleeding/patients with bleeding 
from the site) were 15.4% (6/39) for the olfactory cleft, 
18.2% (8/44) for the middle meatus, 11.1% (4/36) for the 
inferior meatus and 52.5% (21/40) if the bleeding point 
was unknown. Haemostatic procedures at initial examina-
tion for 39 patients with recurrent bleeding were electro-
coagulation (n = 8), gauze tamponade (n = 21), balloon 
tamponade (n = 1) and follow-up (n = 9). The recurrent 
bleeding rates based on the haemostatic procedure were 
8.5% (8/94) for electrocoagulation, 41.2% (21/51) for 
gauze tamponade, 50% (1/2) for balloon tamponade and 
45% (9/20) for follow-up, with electrocoagulation show-
ing the lowest rate of recurrent bleeding. 
Henderson et al.  15 assessed the benefit of implementing 
a standardised treatment protocol for adult epistaxis man-
agement based upon the use of bipolar electrocautery in 
preference to nasal packing. The study compared the re-
sults of epistaxis treatment before and after introduction of 
the protocol. There were 61 and 63 individuals included in 
the pre- and post-protocol groups. The introduction of bi-
polar electrocautery as a treatment modality into the post-
protocol group resulted in a significant change in treat-
ment outcomes. The frequency of nasal packing reduced 
significantly from 34 (56%) to 14 (22%) (p = 0.0002), with 
a corresponding rise in bipolar electrocautery from nil to 
27 (43%) cases. The use of AgNO
3
 remained relatively 
constant between both groups, despite not being on the in-
tervention protocol. Admission rates fell significantly be-
tween the two groups from 38 to 23 (62-37%, p = 0.0068). 
Admissions for social/medical reasons rose very slightly 
in the post-protocol group with an increase in social ad-
missions (5.7%). There were no cases recorded as read-
missions. The overall average hospital length of stay was 
1.2 days for the pre-protocol group, 0.83 days post-proto-
col and 2.4 days for those who underwent nasal packing 
in either group. Using actual numbers of overnight admis-
sions, ward attenders and treatment used, total costs were 
£ 24,706 for the pre-protocol group, and £ 18,175 for the 
post-protocol group. This represented a per-patient aver-
age saving of £ 117, and per year £ 43,345 assuming an 
average of 31 presentations per month.
FloSeal 
The usage of FloSeal haemostatic matrix (Baxter Health-
care, Deerfield, IL, USA), a human thrombin-impregnat-
ed, bovine gelatin matrix, has been evaluated in managing 
epistaxis alone 21 30 or compared to nasal packing 9 13. Kilty 
et al. 21 evaluated this matrix in 20 patients with posterior 
epistaxis. Gelatin-thrombin matrix successfully stopped 
posterior epistaxis in 16 cases (80%). All of these cases 
received a single gelatin-thrombin matrix treatment. Four 
patients (20%) required additional treatment after gelatin-
thrombin matrix failed to stop posterior epistaxis; two had 
surgical treatment; and two had posterior packing. No pa-
tient complications occurred in this study. Anticoagulant 
use was not significantly associated with treatment failure 
(p = 1.0). There was likewise no association with gender 
(p = 0.58), hypertension (p = 1.0), or diabetes (p = 0.62). 
VAS assessment for pain with the gelatin-thrombin ma-
trix treatment had a mean of 3.6. On the other hand, Côté 
et al. 30 observed that epistaxis was adequately controlled 
in 8 of 10 patients without any adverse events. In Lau et 
al. 9, nasal packing controlled epistaxis in 95% (19/20) of 
patients. Eleven patients underwent packing with inflat-
able packs and 9 with nasal tampons. The individual who 
experienced immediate treatment failure had been packed 
with a nasal tampon and epistaxis was controlled after re-
insertion of a second nasal pack. In the FloSeal group, 
epistaxis was controlled in 17 of 20 patients (85%). Of the 
3 patients who experienced immediate treatment failure, 
inflatable nasal packs controlled bleeding in 2. When in-
flatable nasal packing also failed to control the remaining 
person’s epistaxis, she underwent endoscopic sphenopala-
tine artery ligation. There were two readmissions within 7 
days for both groups. The readmission rate was therefore 
10% for both groups. Taking into account the readmis-
sion rate, the overall treatment success rate for nasal pack-
ing was 17 of 20 patients (85%); it was 15 of 20 patients 
(75%) for FloSeal. There was no significant difference 
between the primary outcomes for both groups (p = 0.73). 
Conversely, Khan et al. 13 evaluated FloSeal in 36 of 101 
patients admitted for anterior and posterior epistaxis. The 
total success rate was 14% (5 of 36 cases). It was success-
ful in 2 of 3 cases of anterior epistaxis (66%) and in only 3 
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of 33 cases of posterior epistaxis (9%). Fisher’s exact test 
indicated a significant difference in the success rates of 
FloSeal and nasal packing in the management of posterior 
epistaxis (9% vs 92%, respectively; p < 0.001).
Tranexamic acid
Zahed et al. 19 conducted a trial to assess the efficacy of 
topical tranexamic compared to nasal packing. This ran-
domised clinical trial study was conducted on 216 sub-
jects (124 men and 92 women). Within 10 minutes of 
treatment, bleedings were arrested in 76 (71%) of 107 
patients in the tranexamic acid group, compared with 
34 (31.2%) of 109 patients in the anterior nasal packing 
group (odds ratio, 2.27; 95% CI, 1.68-3.06; p < 0.001). In 
addition, 102 (95.3%) of 107 patients in the tranexamic 
acid group were discharged in 2 hours or less vs 7 (6.4%) 
of 109 patients in the anterior nasal packing group. Re-
bleeding was reported in 5 (4.7%) of 107 and 14 (12.8%) 
of 109 patients during the first 24 hours in the tranexamic 
acid and the anterior nasal packing groups, respectively 
(p = 0.034). After 1 week, re-bleeding in the tranexamic 
acid and the anterior nasal packing groups were 2.8% 
and 11%, respectively (p = 0.018). Satisfaction rate was 
higher with tranexamic acid (8.5 ± 1.7) than with anterior 
nasal packing (4.4 ± 1.8) (p < 0.001).
Silver nitrate
Chemical cautery using the silver nitrate has also been in-
vestigated 20 22. Chemical cautery was the most commonly 
used treatment modality for anterior epistaxis (77.1%) in a 
cohort of 147 individuals 20, and non-dissolvable packing 
was the most common intervention for posterior epistaxis 
(78.6%). The failure rate was 23.8% for all patients un-
dergoing chemical cautery. Among patients with anterior 
epistaxis who underwent chemical cautery, the failure rate 
was 21.0%. All 3 patients who received chemical cautery 
for posterior epistaxis (posterior epistaxis cautery in the 
clinic is done with the use of an endoscope) all experi-
enced treatment failure. The multivariate OR of failure 
was significantly higher for non-dissolvable packing than 
for chemical cautery (6.08; 95% CI, 2.17-17.09) in cases 
of anterior epistaxis. Of note, 4 patients underwent opera-
tive sphenopalatine ligation for their initial epistaxis epi-
sode. All of those patients had posterior bleeding that the 
surgeon believed was of high enough severity that it re-
quired a surgical intervention. Furthermore, Mudunuri and 
Murthy 22 conducted a prospective study on 114 patients. 
Half of patients (n = 57) were managed using conserva-
tive treatment. The other half (n = 57) were treated with 
silver nitrate cautery of the bleeding points/prominent ves-
sels. In the group treated conservatively, 30% (13 cases) 
had at least one episode of epistaxis. In the group treated 
with cautery, 26% (14 cases) had at least one episode of 
epistaxis. No statistical comparison was done.
Endoscopic surgical procedures
Butrymowicz et al. 12 proposed an innovative surgical treat-
ment to control recalcitrant anterior epistaxis based on ana-
tomical dissections, computed tomography (CT) scan and 
small cohort of patients. The authors evaluated the feasibility 
and effectiveness of surgical ligation of the greater palatine 
artery endoscopically. They treated surgically, after careful 
cadaveric dissections and CT scan analyses, 4 patients with 
reasonable efficacy and feasibility of the procedure. 
Shrestha  14 described his personal results on 12 patients 
with epistaxis managed with endoscopical sphenopalatine 
artery ligation under general anaesthesia. Three of 12 pa-
tients developed synechia. However, the success rate in 
controlling epistaxis was 100%. 
George et al.  23 investigated the efficacy sphenopalatine, 
anterior ethmoid and internal maxillary artery interven-
tion in 25 patients. This series included 19 primary en-
doscopic sphenopalatine artery ligations, and three cases 
required adjuvant anterior ethmoid artery surgery. Exclu-
sive anterior ethmoid artery ligation was done in two sub-
jects and was indicated when a suspicious anterior bleed 
refractory to packing or cautery was present. One patient 
underwent embolisation of the internal maxillary artery 
because of high anaesthetic risk. Patients waited on av-
erage 1.9 days for the operating theatre whilst undergo-
ing conservative management for epistaxis. The success 
rate for primary endoscopic sphenopalatine artery ligation 
surgery on the same admission was 89.4% (17/19). 80% 
(20/25) of patients had no further epistaxis episodes fol-
lowing their primary surgery, and so after discharge the 
overall success rate was 88% (22/25). 
In a prospective study, Gandomi et al.  16 endoscopically 
coagulated the sphenopalatine artery in 27 patients. Three 
patients required bilateral cauterisation. All operations in-
volved cauterisation with bipolar diathermy. No patient suf-
fered recurrent epistaxis within the first 24 hours of surgery 
(immediate post-op. period). Three patients suffered recur-
rent epistaxis within 2 weeks following surgery (early post-
op. period), two of whom needed anterior nasal packing 
with the third requiring no medical attention. One further 
patient had recurrent epistaxis within 7 days (early post-op. 
period) and also 2 months after surgery (late post-op. pe-
riod). This patient further responded to conservative man-
agement including local cautery and anterior nasal packing. 
None of these four patients required any new surgical inter-
vention. Therefore, the success rate was 87%. Furthermore, 
in another prospective study, Eladl et al. 28 showed a success 
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rate of 100% and no recurrence of epistaxis in a cohort of 
42 patients after endoscopic sphenopalatine cauterisation. 
Post-operative subjective evaluation of eye dryness indicat-
ed no dryness in 90.5% of patients (n = 38) and mild dryness 
in only 9.5% (four patients, who complained of mild eye 
burning and congestion). Objective evaluation of eye dry-
ness (using Schirmer’s test) was negative in all cases. Post-
operative subjective evaluation of nasal dryness indicated 
that dryness was present in 81% of patients (n = 34), but 
was severe in only 9.5% (n = 4), and resolved with medical 
treatment (i.e. nasal debridement and irrigation). Post-oper-
ative subjective evaluation for nasal sensation (i.e. para-aes-
thesia or hypoaesthesia of the nose, upper teeth and palate) 
indicated numbness and para-aesthesia of the upper teeth 
in three patients. Objective evaluation of nasal sensation 
found hypoaesthesia of the nasal mucosa in eight patients, 
but without any patient complaint. No hypoaesthesia of the 
hard palate was detected. No major post-operative compli-
cations or irreversible damage was encountered. Similar 
results, achieving the control rate of 93%, were described 
in the study of Minni et al. 31 (42 sphenopalatine artery and 
6 anterior ethmoidal artery ligations).
Endovascular embolisation
Gottumukkala et al.  18 reviewed their experience with 
routine multivessel embolisation for intractable idiopath-
ic epistaxis in 84 patients and examined the association 
between the number of vessels receiving embolisation 
and treatment outcomes. Embolisation of bilateral inter-
nal maxillary artery (IMA) with or without facial artery 
embolisation was performed in 76 patients (41 with one 
or both facial arteries, 35 without facial artery). In cases 
where embolisation of three vessels was performed, the 
facial artery treated was always ipsilateral to the bleed-
ing site. In 10 patients, it was unclear which side was the 
source of bleeding. Four of these patients received bilat-
eral IMA and bilateral facial artery embolisation, whereas 
six received bilateral IMA embolisation alone. Successful 
treatment (no re-bleeding within 30 days) was achieved 
in 75 patients (89%). Of the nine patients who had early 
re-bleeding, 6 experienced re-bleeding within 1 day of 
embolisation and did not require additional hospital ad-
mission. All nine patients required some form of retreat-
ment, including surgical ligation of the ipsilateral anterior 
or posterior ethmoidal arteries (n = 6), endoscopic elec-
trocautery (n = 4), and repeat embolisation (n = 1). There 
was one major complication (1%). A patient who under-
went bilateral IMA and bilateral facial artery embolisa-
tion experienced skin sloughing of the chin, submandibu-
lar pain and oedema that caused difficulty swallowing, 
and severe lip oedema with mild ulceration. The oedema, 
pain and ulceration subsided by 1-month follow-up; the 
skin sloughing resolved by 8 weeks. Minor complications 
occurred in 22 patients (26%).
In another retrospective study 25, 16 patients were evaluat-
ed. After embolisation, immediate cessation of bleed was 
achieved in all 16 (100%) patients. However, in 2 (12.5%) 
of cases angioembolisation had to be repeated; in 1 pa-
tient on the same day and in another patient after a month. 
Thus, the overall success rate was 87.5%. In majority of 
cases (56.25%), ipsilateral IMA was the bleeding source 
and was embolised.
Lesley et al. 27 studied the efficacy and safety profile of de-
tachable platinum fibered coil embolisation in a cohort of 
20 patients. Seventeen patients underwent bilateral IMA 
embolisation. Three patients had unilateral IMA embosur-
gery of which two had previously undergone contralateral 
IMA open ligation for remote, but severe bouts of epistax-
is. During the 30-day follow-up period, 95% of the cohort 
remained free of recurrent nose bleeding that required 
medical or surgical intervention. Open surgical anterior 
ethmoid cauterisation was needed to control bleeding in 
one patient (5%) who re-bled 4 days after embosurgery. 
95% of patients had no complications, while one patient 
(5%) had short-lasting, transient unilateral facial pain. 
Strach et al. 29 evaluated 48 patients suffering from intrac-
table epistaxis underwent angiography and selective intra-
arterial intervention. In this series, a total of 31 individu-
als presented with idiopathic epistaxis. The success rate 
after first-time embolisation was 29 of 31 (93.5%). After 
ineffective unilateral embolisation of the sphenopalatine 
artery in one patient (1/31; 3.2%), second-phase emboli-
sation of the contralateral sphenopalatine, the descending 
palatine and branches of the facial artery, and, in a third 
phase, the ipsilateral sphenopalatine artery was performed, 
which finally lead to cessation of epistaxis increasing the 
success rate in group 1 to 96.8% (30/31). Despite bilateral 
embolisation of the sphenopalatine arteries, one patient 
(1/31; 3.2%) had to undergo surgical coagulation of the 
ethmoidal artery to achieve haemostasis. One patient with 
initially successful unilateral embolisation of the spheno-
palatine artery experienced reoccurrence of epistaxis after 
an asymptomatic period of 14 days and underwent addi-
tional septoplasty, thereby achieving haemostasis. Thus, 
the overall long-term success rate was 93.5%.
Laser
Zhang and Qiu  26 conducted a prospective, randomised, 
single-blinded study on the use of Nd:YAG laser for treat-
ment of anterior epistaxis. A total of 80 consecutive pa-
tients were included and equally divided into Laser and 
ointment groups. After 12 weeks, 85% of laser patients 
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and 40% of control patients had no reported bleeding. The 
outcome score of the 80 patients at 4 weeks after treatment 
showed no significant differences between groups (mean 
rank: 43.93 vs 37.08, ointment group versus laser group, 
p = 0.130). However, the outcome score at 12 weeks after 
treatment showed a significant difference between the two 
groups (mean rank: 49.60 vs 31.40, ointment group versus 
laser group, p < 0.01). Neither experimental group had com-
plications, such as blood transfusion, hospitalisation, visible 
nasal scars, nasal adhesions, or nasal septum perforation.
Discussion
The purpose of this study was to examine recent concepts 
in managing idiopathic epistaxis. Nasal packing still repre-
sents the first-line approach to epistaxis, although, at pre-
sent, it appears that there is clear evidence in the literature 
suggesting that it is less effective and associated with more 
admissions and longer hospital stays than endoscopic elec-
trocoagulation-based management of epistaxis. In 65% to 
70% of cases of epistaxis, simple first aid measures provided 
by the primary care physician or emergency physician are 
effective. If bleeding persists, patients should be urgently re-
ferred to the ENT Department. So long as the source of the 
bleeding is visible, most cases of epistaxis can be success-
fully treated using electrical or chemical cautery. For pos-
terior epistaxis, surgical intervention is markedly superior 
to packing. The method of choice is endoscopic clipping 
or coagulation of the sphenopalatine artery, which controls 
bleeding in 98% of cases 32. Early sphenopalatine ligation 
has a cost-effective profile, while a randomised prospective 
trial of early ligation vs nasal packing found an overall cost-
savings of approximately $ 7080. Additionally, the length 
of stay was less than half that for nasal packing. A 2003 
retrospective study by Klotz et al. 33 found that ligation had 
a mean length of stay of 2.1 days and $ 3851 of associated 
costs. Moreover, Henderson et al. 15 conducted an analysis 
on costs before and after application of a protocol teaching 
junior physicians on the use of cauterisation instead of nasal 
packing. They found a per-patient average saving of £ 117, 
and per year £ 43,345 assuming an average of 31 presenta-
tions per month. Its cost-effectiveness was also confirmed 
in the management of posterior epistaxis with endoscopic 
sphenopalatine ligation instead of traditional nasal packing. 
Dedhia et al. 34 found, in the base case, costs for first-line 
endoscopic sphenopalatine ligation and current practice (na-
sal packing) arms were $ 6450 and $ 8246, respectively. In 
other words, there was a cost savings of $ 1796 in the first-
line endoscopic sphenopalatine ligation arm.
On the other hand, endovascular interventions are an im-
portant option for the treatment of life-threatening posterior 
epistaxis. Percutaneous embolisation is highly efficient and 
its safety profile compares favourably with alternative ther-
apeutic modalities. It is noteworthy that, unlike other treat-
ment strategies, major complications, such as cerebrovas-
cular embolism or soft-tissue damage, may occur. Hence, 
this approach should be the last option and to be used only 
when all other options fail or in the presence of severe co-
morbidities that might preclude general anaesthesia 35.
Finally, data concerning the use of drugs (i.e. tranexamic 
acid) or other medical devices did not show a substantially 
stronger clinical applicability. This is due to the fact that 
the data are extrapolated from few studies usually with a 
small cohort of patients, and most are neither randomised 
nor comparative. 
Conclusions
Currently, the most common first-line treatment of idio-
pathic epistaxis is nasal packing, although there is a clear 
trend away from the use of nasal packs. Although it is 
a quick and easy to learn technique, emerging evidence 
show that cauterisation provides economic advantages 
and is easy to teach, especially for anterior epistaxis, to 
non-otolaryngologists. Early sphenopalatine artery liga-
tion should also confer financial advantages, while the use 
of endovascular techniques should be reserved as a last 
option. Further research is urgently needed to assess the 
efficacy of new biomaterials that might have a significant 
impact on first-line management.
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